28 results about "Choroid" patented technology

The present application relates to the field of traditional Chinese medicine, in particular to a kind of traditional Chinese medicine composition for treating central serous chorioretinopathy and application thereof.The present application provides a kind of traditional Chinese medicine composition for treating central serous chorioretinopathy, compared with the prescription of Chunzai Decoction, the traditional Chinese medicine composition of the present application increases the efficacy of promoting blood circulation and removing blood stasis, soothing the liver and relieving depression, clearing the liver and improving eyesight, clearing heat and reducing phlegm on the basis of Chunzai Decoction warming yang, transforming qi, reducing water and removing dampness;Compared with using Chunzai Decoction alone, the curative effect of patients using the traditional Chinese medicine composition is more direct, from 2-3 weeks to 1 week, and the curative effect is accelerated.And the traditional Chinese medicine composition of the present application has been used for about 2 years, 2 / 3 of the 112 patients can see effect in 1 week, and no recurrence is found within 3 months.

An ocular access instrument (20) includes an attachment assembly (32) configured to engage a sclera of an eye, and an actuator assembly (34) configured to bear against the sclera. When the attachment assembly engages the sclera, movement of the actuator assembly inwardly against the eye displaces the choroid from the sclera, thereby creating an enlarged suprachoroidal space. The ocular access instrument may also include a needle guide (40) configured to receive the needle and guide the needle into the enlarged suprachoroidal space.

The invention discloses a pathological myopic lesion classification method, system and device and a medium, belongs to myopic lesion classification in artificial intelligence medicine, and aims to solve the technical problem that choroidal lesion classification accuracy is low due to the fact that diagnosis complexity cannot be captured when multiple pathological myopic lesions exist at the same time are classified in the prior art. The method comprises the following steps: acquiring an OCT sample image and a label, constructing and training a myopic lesion classification model, and performing real-time classification; the myopia lesion classification model comprises a shared encoder, a segmentation decoder and a classification decoder; the shared encoder comprises four residual blocks which are arranged in sequence; the segmentation decoder is a semi-supervised divider; the classification decoder comprises a focus focusing module, a pyramid structure feature fusion module and a classification module which are arranged in sequence. A myopia lesion classification model is creatively constructed, a segmentation decoder can automatically identify a choroid structure in an OCT image, and the blank between a traditional clinical index and a deep learning diagnosis system is effectively filled.

The invention relates to the technical field of lighting equipment, in particular to a negative oxygen ion eye-protection lamp capable of inhibiting myopia and relieving asthenopia, which comprises an eye-protection lamp body, a lamp post and a negative oxygen ion generator, the eye-protection lamp body is used for emitting full-spectrum light; the negative oxygen ion generator is installed at the joint of the eye protection lamp body and the lamp pole, and the concentration of negative oxygen ions generated by the negative oxygen ion generator is 5000-5000 / cm < 3 >. When the eye protection lamp is used, the negative oxygen ion generator is arranged at the joint of the eye protection lamp body and the lamp pole, the negative oxygen ion generator can generate negative oxygen ions with the concentration of 5000-50000 / cm < 3 >, more dopamine is secreted by a living body through the negative oxygen ions, the fundus blood flow density and the fundus retina cell activity are improved, the choroid thickness is increased, and therefore the eye protection effect is improved. Therefore, the visual comfort is improved, and the effects of inhibiting myopia and relieving asthenopia are achieved.

The present application relates to the field of ophthalmic medical technology, especially to an eyeball cornea treatment system based on near-infrared light recognition, which acquires optical information of eyeball cornea and choroid by collecting near-infrared light signals, and performs digitalization and filtering processing on the original image to output processed image data. Combining edge detection and threshold segmentation, choroid defects or atrophic lesion points are identified, and corneal thickness and curvature are measured to determine the energy intensity, irradiation time, wavelength and focusing position of the excimer light beam. According to the parameters, an excimer light beam with a wavelength of 248 nanometers is emitted to irradiate and treat the lesion area, which improves the positioning accuracy of the lesion while avoiding damage to normal tissue structures, and meets the safety and effectiveness requirements of eye treatment.

The utility model relates to an organ model which comprises a model body with an inner cavity, a plurality of red venation bodies and a plurality of purple venation bodies for simulating blood capillaries are arranged in the side wall of the model body, and the red venation bodies and the purple venation bodies are located on the side close to the inner surface of the model body. The red venation body and the purple venation body are arranged on the inner surface of the model body, so that the red venation body and the purple venation body are visible from the inner surface of the model body, a plurality of surface venation bodies for simulating coarse vessels are arranged on the inner surface of the model body, and a transparent adhesive layer for simulating mucous membranes is arranged on the inner surface of the model body. The surface vein body is located between the transparent adhesive layer and the inner surface of the model body. The structure and the color level of the blood vessel on the organ model are more consistent with the reality, so that the evaluation test of the image is more in line with the clinical requirements, the manufacturing is simple, the storage is convenient, the test cost can be reduced, the reutilization can be realized, the resource waste is avoided, and the continuity and the result stability of the evaluation test are good.

The utility model provides a display device and a learning tablet, the display device comprises a display screen and an eye protection illumination module, the eye protection illumination module comprises a preset eye protection light source, and the eye protection illumination module is arranged in a reciprocating sliding mode relative to the display screen so as to be stored behind the display screen or extend out of the display screen area; and after extending out of the display screen area, the light source is started to irradiate human eyes. According to the application, the eye protection illumination module independent of the display screen is utilized to irradiate the human eyes, through the non-invasive photobiological regulation effect, the choroid thickness and the retinal metabolism are enhanced, the asthenopia is relieved, meanwhile, myopia development is inhibited from the source, and the incidence rate of myopia is effectively reduced.

An ocular implant system is described herein in which an implant (200) is deployed in the posterior space of an eye - e.g., the suprachoroidal space or the subconjunctival space or the intrascleral space - through an access in the anterior chamber (160) for reducing intraocular pressure in the eye. The shunt device (200) is implanted using an implantation device that includes a hollow shaft (330) mounted on a fixed shaft (320). The shunt device (200) is located in the distal end of the hollow shaft (330) and adjacent to the distal end of the fixed shaft (320) at a location behind the distal end of the hollow shaft. Once the distal end of the hollow shaft (330) and the shunt device (200) are at the desired depth within the posterior space, the hollow shaft is withdrawn over the fixed shaft through the access in the anterior chamber (160) towards the proximal end of the fixed shaft, leaving the shunt device in the posterior space.

A stent implant for treating glaucoma by intraocular fluid drainage from the anterior chamber, for example into the suprachoroidal space. The stent implant is designed to change in shape after being inserted into the eye, during which change the width and / or thickness or the flow cross-section is increased by for example 20%, in another example more than 200%, and in a further example by more than 400%, at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can be largely or completely closed. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. The implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

The present disclosure relates to a medicine depth delivery device, which comprises a delivery part with a containing structure for containing a medicine, a needle connected with the containing structure, and a positioning part sleeved on the needle, the positioning part having a positioning structure and a scale arranged at the bottom end thereof, the positioning structure comprising a first positioning structure and a second positioning structure, the first positioning structure and the second positioning structure being flipped towards the radial outside of the body relative to the body, the first positioning structure having a first opening with the body, the second positioning structure having a second opening with the body, and the opening directions of the first opening and the second opening being opposite to each other. By being provided with the positioning structure and the positioning part with the scale, the positioning part can be fixed to the desired position in the case of delivering the medicine to the choroid and scleral space, and the effect of high-precision depth delivery is achieved in combination with the previously measured scleral thickness.

Provided are formulations and methods for treating patients having AMD, by inhibiting formation or growth of drusen, and / or reducing number and / or size of drusen, while maintaining or restoring ellipsoid zone area in a human eye.

The invention discloses a red-light small-hole optical lens for preventing and controlling axial myopia and a manufacturing method of the red-light small-hole optical lens. Relates to the technical field of optical lenses, and comprises a lens base body and a plurality of optical functional areas arranged on the lens base body, each functional area has different light transmittances for 620-650 nm red light, and the light transmittances are gradually distributed from the center of the optical functional area to the edge of the optical functional area by 10%-99.99%. The optical function area comprises but is not limited to a three-area or four-area structure, and a red dot diffusion effect from deep to light is formed through cooperation of the light transmittance of all the areas. Red light with a specific wavelength can be projected to retina and choroid areas in a dispersion manner, and choroid blood circulation is improved through a photobiological effect, so that the growth of an ocular axis is inhibited. And the optical functional area is manufactured through a process of combining red light pulse laser internal micro-engraving or ultraviolet laser surface etching with high-transmittance red light film layer lamination. Red light treatment and daily glasses are combined, and all-weather and living myopia prevention and control are achieved.

The invention relates to an eye essence stock solution and a preparation method thereof. The eye essence stock solution comprises a traditional Chinese medicine compound extraction concentrated solution. The traditional Chinese medicine compound comprises ligusticum wallichii, liquorice, fructus lycii, salvia miltiorrhiza, nacre mother of pearl, caulis spatholobi, angelica sinensis, pseudo-ginseng, cornu cervi pantotrichum, crocus sativus, semen cassiae and selaginella tamariscina. According to the essence stock solution, through the synergistic interaction of all the components in the traditional Chinese medicine compound, the essence stock solution penetrates through skin to directly reach fundus, clears and activates channels and collaterals, warms channels and dispels cold, promotes blood circulation of eyes, effectively improves nutrition of tissues around the eyes, relaxes ciliary muscles which are tense and shrunk for a long time, and enables choroids to be hyperemia and thickened so as to play a role in regulating and controlling myopia.

Provided are formulations and methods for treating drusen and / or AMD, such that the risk of vitreous flare and lens opacity or lens haziness, e.g., cataract formation, is reduced or substantially eliminated.

Conventional ways of reducing pressure in the eye have inherent drawbacks and one such way to reduce these drawbacks is to provide an ocular drainage implant including a pliable plate which is so sized and shaped as to enable it to be positioned on a sclera surface or a sub-scleral space of an eye comprising a first exterior face and a second exterior face, with a plurality of apertures extending between the first and second faces, and a fluid drainage tube retaining structure; and a valve-less fluid drainage tube connected to the retaining structure and providing the implant with a longitudinal axis, the valve-less fluid drainage tube being adapted to drain fluid from an anterior chamber of the eye to the subconjunctival or the suprachoroidal space, wherein the retaining structure extends substantially across an entire dimension of the plate.

This invention discloses a method and system for quantitative analysis of the choroidal capillary layer, relating to the field of vascular imaging technology. The key technical points are: acquiring OCTA volume data; extracting en-face projection images from the OCTA volume data, where the en-face projection images reflect blood flow distribution information in the CC layer; performing dynamic thresholding on the en-face projection images to generate binarized or significantly enhanced images, obtaining the boundary position between the CC layer and the Sattler layer; mapping the boundary position back to the OCTA volume data; determining the lower boundary position of the CC layer in the structural B-scan image sequence corresponding to the OCTA volume data, thus completing the three-dimensional segmentation of the CC layer. This invention achieves stable, repeatable, and accurate definition of the three-dimensional anatomical range of the CC layer, overcoming the shortcomings of existing technologies that rely on fixed thresholds or single image modalities, resulting in subjective segmentation and poor individual adaptability.

This disclosure generally relates to the field of ophthalmic therapies, and more particularly to the treatment of various eye diseases and conditions by the non-surgical administration into a subject's eye of a pharmacological composition described herein containing a plasma kallikrein inhibitor. Avoralstat is included among the plasma kallikrein inhibitors. The compositions and methods include the administration of a plasma kallikrein inhibitor into the suprachoroidal space (SCS) of the eye.

The disclosure relates to ophthalmic implants, specifically a flexible, self-expanding spacer device deployable in subconjunctival, sub-Tenon's, or suprachoroidal spaces to manage intraocular fluids. The device addresses limitations of fixed-resistance drainage and fibrosis-related failure in glaucoma surgery by maintaining a controlled three-dimensional reservoir (bleb space) for aqueous humor outflow while minimizing tissue trauma. In one aspect, a shape-memory body transitions from a compressed, delivery-compatible state to an expanded configuration defining a convex internal volume, optionally with collapse-resistant reinforcements and tissue-engaging elements for atraumatic stabilization. Preferred embodiments include anterior relief geometry to avoid corneal contact and posterior flow-directing features to promote posterior bleb formation and uniform pressure control. A delivery member with a reduced-profile, tapered piercing tip and optional bent shaft enables minimally invasive ab externo implantation and controlled, coaxial deployment. Advantages include streamlined single-step delivery, stable long-term bleb architecture, reduced hypotony and fibrotic encapsulation, and compatibility with trabeculectomy and shunt-based outflow.

This invention relates to the field of biotechnology and discloses a method for screening drugs capable of preventing and / or treating posterior segment diseases of the eye. The method includes: first, decompressing the anterior chamber of an experimental animal; then, pre-establishing a "perforation-closure" channel in the sclera of the experimental animal; next, injecting the drug to be screened into the suprachoroidal space of the experimental animal through the "perforation-closure" channel in the sclera; and finally, evaluating the effectiveness of the drug in preventing and / or treating posterior segment diseases based on changes in the eye condition of the experimental animal. This invention reduces the incidence of ocular surface inflammation and improves safety by lowering intraocular pressure and creating a pre-closed scleral incision to prevent backflow of the injected AAV vector; it also provides a broader expression range and longer duration of action. Studies have shown that injecting shRNA targeting the TGF-β2 gene using the method of this invention inhibits myopia progression in a guinea pig model. The method provided by this invention is beneficial for screening gene therapy drugs related to posterior segment diseases.

Ocular implants, kits and methods are disclosed. In one arrangement, an implant comprises a frame deployable in the suprachoroidal space of an eye and configured to resiliently adopt an arched elongate shape to promote drainage of aqueous humor through the suprachoroidal space when the frame is deployed in the suprachoroidal space. Relative to an axis of elongation of the elongate shape: the frame has a first axial end and a second axial end; and the arched elongate shape defines a channel. The channel has a first axial opening at the first axial end of the frame, a second axial opening at the second axial end of the frame, and a longitudinal opening extending continuously from the first axial end to the second axial end.

The application provides use of an ELN gene or a plasmid or virus containing the same in preparation of a medicament for repairing aging choroid and / or retinal pigment epithelium. The application constructs an ELN overexpression vector, overexpresses the gene in a mouse eyeball, increases actin in a choroid layer and an RPE layer, and is beneficial to maintaining the structural morphology of the choroid and the RPE layer; and can maintain the tightness of a basal surface of the RPE layer and the integrity of the RPE structure, maintain the smoothness of a fiber structure of the choroid layer, and has no obvious influence on blood vessels and pigments of the choroid layer. It is illustrated that the ELN gene can be used for improving relaxation of the choroid and the RPE structure, remodeling the aging choroid and the RPE, and has application prospects in preparation of a medicament for repairing aging choroid and / or retinal pigment epithelium, such as a medicament for preventing and treating age-related macular degeneration.

This disclosure is generally in the field of ophthalmic therapies, and more particularly to the treatment of various ocular diseases and conditions by non-surgical administration to the eye of a subject of a drug composition described herein containing a plasma kallikrein inhibitor. Plasma kallikrein inhibitors include avoralstat. The compositions and methods include delivery of a plasma kallikrein inhibitor to the suprachoroidal space (SCS) of the eye.

Minimally invasive, implantable ophthalmic drainage devices and systems for delivering the drainage devices are disclosed. The disclosed drainage devices may allow more stable implantation in the suprachoroidal space of an eye and control of fluid drainage from the eye for treating glaucoma. The disclosed delivery systems may improve control and reduce difficulty of device implantation.

The choroid suture fixing device comprises a pusher, a front-end suture nail, a plurality of middle suture nails, a rear-end suture nail and a suture thread; the pusher comprises a pusher barrel and a pusher rod, the pusher barrel is open at the front end, the pusher rod is inserted in the pusher barrel and axially penetrates the rear middle part of the pusher barrel; the rear side end of the front-end suture nail, the plurality of middle suture nails and the rear-end suture nail is provided with a threading hole, the front end of the suture thread is fixed on the threading hole of the front-end suture nail, the middle section penetrates the threading holes of the middle suture nails in sequence and the rear end is fixed on the threading hole of the rear-end suture nail; the front-end suture nail, the plurality of middle suture nails and the rear-end suture nail with the suture thread are respectively arranged in the front middle part of the pusher barrel and arranged at the front end, the middle section and the rear end in sequence, and the forces are mutually cooperative when they are sutured and fixed on the choroid, so that the force of the whole choroid suture fixing part is uniform, the fixation is more firm and stable and the device can be operated by one hand.

The application discloses a spectrum visual effect analysis system and method connected with a spectrometer. The system comprises a spectrum power distribution data transmission module for receiving spectrum power distribution data measured by the spectrometer; and a spectrum human eye physiological effect calculation module for receiving the spectrum power distribution data transmitted by the spectrum power distribution data transmission module, and acquiring spectrum contrast sensitivity effect parameters, spectrum aberration effect parameters, spectrum ocular fundus blood flow effect parameters, spectrum choroid effect parameters and the like according to the received spectrum power distribution data. The application can enable a user to calculate physiological effects of spectrum in real time and synchronously while measuring spectrum power distribution of a lamp by using the spectrometer, so as to evaluate the risk of visual fatigue caused by the spectrum of the lamp, and to adjust the use of eyes in time.

To provide an improved apparatus for delivering medicament to a suprachoroidal space of an eye.SOLUTION: According to one aspect of the disclosure, an apparatus for manipulating a sclera to facilitate delivery of a medicament to a suprachoroidal space of an eye may include a needle with a sharp distalmost tip, a needle hub connected to a proximal end of the needle, a housing surrounding the needle hub and extending from a proximal end of the needle hub, and an adaptor surrounding a portion of the needle.SELECTED DRAWING: Figure 2

The invention relates to the technical field of lighting equipment, in particular to an eye protection lamp capable of inhibiting myopia and relieving fatigue, which comprises a shell and a negative ion generator, a substrate, a light source module and a light guide plate are sequentially arranged in an inner cavity of the shell from inside to outside, and the light source module is provided with a blue light bead group, a purple light bead group and a dark red light bead group. The wavelength of a light source emitted by the light source module ranges from 385 nm to 780 nm, the wavelength of a light source emitted by the purple light lamp bead set ranges from 385 nm to 420 nm, and the wavelength of a light source emitted by the dark red light lamp bead set ranges from 650 nm to 780 nm. During use, the ultraviolet lamp bead group with the light source wavelength of 385-420 nm and the dark red lamp bead group with the light source wavelength of 650-780 nm are arranged in the light source module and are matched with the negative ion generator for use, so that organisms are promoted to secrete more dopamine, the fundus blood flow density and the fundus retina cell activity are improved, the choroid thickness is increased, and the growth of the ocular axis is inhibited; the vision comfort is improved, myopia is inhibited, the blood oxygen concentration is increased, free radicals in the body are eliminated, and fatigue is relieved.